Osteodystrophy
Osteodystrophy is abnormal bone formation or turnover, most commonly used clinically for renal osteodystrophy caused by chronic kidney disease.
Key takeaways
- Kidney disease disrupts phosphate removal, vitamin D activation and parathyroid regulation, producing several different bone-turnover patterns.
- PTH, calcium and phosphate trends guide care but do not identify bone type perfectly; treatment should avoid over-suppression.
- Phosphate binders, vitamin D analogues and calcimimetics have distinct roles and can cause calcium imbalance.
The listings below are not interchangeable mineral supplements; nephrology should interpret stage, trends and dialysis context.
Defining the mineral-bone disorder
Clinicians track calcium, phosphate, alkaline phosphatase, PTH and vitamin D alongside kidney function. Bone pain and fractures may occur, while vascular and soft-tissue calcification are also major concerns. Bone biopsy is reserved for cases where the result would change treatment.
Treatment priorities
Dietary phosphate management, binders, vitamin D forms, calcimimetics and dialysis adjustment have distinct roles. Calcium loading is limited when vascular calcification risk is high. Parathyroid surgery may be considered for severe refractory hyperparathyroidism.
When to seek urgent care
Seek urgent care for severe muscle spasms, seizure, confusion, a new abnormal heart rhythm, sudden severe bone pain or inability to use a limb after minor trauma.